2023 · Journal of pharmaceutical and biomedical analysis · paywalled
A sensitive liquid chromatographic-mass spectrometry method for the quantification of vincristine in whole blood collected with volumetric absorptive microsampling
van et al.
The finding, in our words
A validated LC-MS/MS method successfully quantified vincristine in paediatric patient-centric whole blood collected via VAMS microsampling, spanning 1 to 50 ng/mL with intra- and inter-accuracy and precision within ±10.3% and ≤7.3%. Whole blood concentrations showed a non-linear relationship to plasma concentrations, which was described by a saturable binding model.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
A 2025 review maps 28 microsampling devices, from dried spots and volumetric absorptive tips to upper-arm liquid capillary collectors, and names what a laboratory must control before their results are used: the haematocrit effect in non-volumetric dried samples, interstitial fluid from finger milking, volume, haemolysis and transport stability. Regulators on both sides of the Atlantic ask for the same two things, a device the patient can use safely and a sample fit for the test.
An on-line SPE-LC-MS method using 10 microlitre capillary blood samples collected on VAMS tips achieved lower limits of quantitation of 0.03 micromolar for methotrexate and 7-OH-MTX and 0.05 micromolar for DAMPA, with acceptable accuracy and precision. A plasma-to-whole-blood correlation factor of 0.46 was observed, supporting low-volume pediatric drug monitoring.
Opitz et al., Journal of chromatography. A (paywalled) · source ↗
This narrative review evaluates microsampling devices for therapeutic drug monitoring, concluding that techniques such as volumetric absorptive microsampling and dried blood spots offer reliable, less invasive alternatives to venous sampling when paired with high-sensitivity mass spectrometry, which supports implementation in routine clinical practice.
A review of dried blood microsampling for tyrosine kinase inhibitor monitoring, covering the analytical and clinical requirements for moving oral cancer-drug TDM out of hospital.
Verougstraete et al., Frontiers in Oncology · source ↗
In AML and CLL, 91% of VAMS venetoclax results fell within 20% of plasma after individualised haematocrit correction; in home sampling, 18 of 21 patients self-sampled independently and 76% of returned samples were analysable, which shows home microsampling is workable, though the authors ask for multicentre validation.
Levens et al., Clinical Pharmacokinetics (paywalled) · source ↗